Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Northmirs Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 1 distinct examiner, which is a notable concentration of workload for multiple pending matters. Furthermore, the company's prosecution activity is confined to 1 distinct art unit, indicating that the 2 pending office actions likely involve closely related biological or pharmaceutical technologies.
The busiest examiner for the portfolio is SHIN, DANA H, who is responsible for 2 busiest examiner pending actions. This means that the same individual is reviewing every active application the company has before the patent office. For the applicant, this concentration under SHIN, DANA H provides a consistent examination environment but also means that the company's entire Biotechnology & Pharmaceuticals strategy is subject to the interpretation of a single examiner.
Managing 2 pending office actions within 1 distinct art unit requires a coordinated response strategy to ensure that arguments made in these cases do not conflict. Since 1 distinct examiner is handling these matters, the company has a unique opportunity to understand and adapt to the specific requirements of the assigned official. The 2 busiest examiner pending actions represent the full scope of the company's current challenges in the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIN, DANA H | 2 | 26.9% | +26.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18933178 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | — |
| 18794415 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18933178 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | — |
| 18794415 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18933178 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | 1635 | §103§112 | Final Rejection | — | Pending | Oct 31, 2024 |
| 18794415 | MICRORNA-BASED PARTICLE FOR THE TREATMENT OF DYSREGULATED IMMUNE RESPONSE | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Aug 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNorthmirs Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dana H Shin has the most, with 2 of Northmirs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
